Carlos Alberto Pastore | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Prof. Carlos Alberto Pastore | Medicine and Health Sciences | Best Researcher Award

Heart Institute of the Hospital das Clínicas of FMUSP | Brazil

Prof. Carlos Alberto Pastore is a distinguished cardiologist and researcher from the University of São Paulo, Brazil, internationally recognized for his pioneering work in electrocardiology and vectorcardiography. As a Professor and Medical Collaborator at the Faculty of Medicine, University of São Paulo (FMUSP), he has significantly advanced diagnostic methods for cardiac electrical diseases, cardiac mapping, and non-invasive electrocardiographic techniques. His research specializes in surface electrocardiographic mapping, high-resolution ECG, microalternans of the T wave (mTWA), and vectorcardiographic analysis of ventricular activation and repolarization abnormalities. Prof. Carlos Alberto Pastore has played a vital role in refining diagnostic criteria for arrhythmogenic disorders, ventricular hypertrophy, and cardiac resynchronization therapy, and he has applied artificial neural networks and machine learning in ECG-based cardiopathy detection in collaboration with the Federal University of Technology of Paraná (UTFPR). At InCor – Heart Institute (Hospital das Clínicas, FMUSP), he has held major roles including Director of the Clinical Unit of Resting Electrocardiography, Medical Director of Telemedicine, and Vice-President of the Zerbini Foundation, contributing to translational cardiology and digital health innovation. He also served as President (2013–2015) of the International Society of Electrocardiology (ISE) and is a Fellow of the European Society of Cardiology (FESC). According to Scopus (Author ID: 7006635654), Prof. Carlos Alberto Pastore has authored 53 scientific publications, received 1,014 citations from 948 documents, and holds an h-index of 12. His research has appeared in leading journals including the Journal of Electrocardiology, Annals of Noninvasive Electrocardiology, Arquivos Brasileiros de Cardiologia, and JACC, making him one of Brazil’s leading authorities in clinical electrocardiology and cardiovascular diagnostics.

Profiles: Scopus | Google Scholar | ORCID | ResearchGate

Featured Publications

• de Luna, A. B., Brugada, J., Baranchuk, A., Borggrefe, M., Breithardt, G., & Pastore, C. A. (2012). Current electrocardiographic criteria for diagnosis of Brugada pattern: A consensus report. Journal of Electrocardiology, 45(5), 433–442.* https://doi.org/10.1016/j.jelectrocard.2012.06.004

• de Luna, A. B., Platonov, P., Cosio, F. G., Cygankiewicz, I., Pastore, C., Baranowski, R., … & Spodick, D. (2012). Interatrial blocks: A separate entity from left atrial enlargement: A consensus report. Journal of Electrocardiology, 45(5), 445–451.* https://doi.org/10.1016/j.jelectrocard.2012.06.008

• Pastore, C. A., Pinho, J. A., Pinho, C., Samesima, N., Pereira Filho, H. G., & Mansur, A. P., et al. (2016). III Diretrizes da Sociedade Brasileira de Cardiologia sobre análise e emissão de laudos eletrocardiográficos. Arquivos Brasileiros de Cardiologia, 106(4 Suppl 1), 1–23.* https://doi.org/10.5935/abc.20160054

• Santos, I. S., Goulart, A. C., Brandão, R. M., Santos, R. C. O., Bittencourt, M. S., Sitnik, D., … & Pastore, C. A. (2015). One-year mortality after an acute coronary event and its clinical predictors: The ERICO study. Arquivos Brasileiros de Cardiologia, 105(1), 53–64.* https://doi.org/10.5935/abc.20150049

• Digby, G. C., Kukla, P., Zhan, Z. Q., Pastore, C. A., Piotrowicz, R., Schapachnik, E., … & Baranchuk, A. (2015). The value of electrocardiographic abnormalities in the prognosis of pulmonary embolism: A consensus paper. Annals of Noninvasive Electrocardiology, 20(3), 207–223.* https://doi.org/10.1111/anec.12235

Tuncay Kiris | Medicine and Health Sciences | Forensic Scientist of the Year Award

Published on by Forensic Scientist

Assoc. Prof. Dr. Tuncay Kiris | Medicine and Health Sciences | Forensic Scientist of the Year Award

Izmir Katip Çelebi University Atatürk Training and Research Hospital | Turkey

Dr. Tuncay Kırış, an Associate Professor at İzmir Kâtip Çelebi University, Izmir, Turkey, is a distinguished cardiology researcher recognized for his extensive contributions to cardiovascular medicine, particularly in the fields of cardiovascular risk prediction, interventional cardiology, acute coronary syndromes, and cardiac biomarkers. His research has provided valuable insights into myocardial infarction, pulmonary embolism, renal complications following cardiac interventions, and the prognostic implications of biochemical and hematological markers in predicting patient outcomes. Dr. Tuncay Kırış has authored 83 peer-reviewed publications in prestigious international journals indexed in SCI and SCI-Expanded, including Angiology, BMC Cardiovascular Disorders, The Anatolian Journal of Cardiology, Clinical and Experimental Hypertension, Herz, and Acta Radiologica. His works have received 591 citations from 544 documents, with an h-index of 15, according to Scopus (Author ID: 55321350600), reflecting his strong academic impact. His studies emphasize innovative predictive and prognostic modeling approaches, such as exploring the fibrinogen-to-albumin ratio, red cell distribution width, and lymphocyte-to-monocyte ratio as novel indicators of adverse cardiovascular events and renal complications. Beyond his research, he has supervised postgraduate theses on cardiovascular risk assessment, contributed to collaborative projects in clinical and translational cardiology, and serves as Editor of the Ege Klinikleri Tıp Dergisi. As an active reviewer for several international cardiology journals, Dr. Tuncay Kırış continues to advance evidence-based cardiology through data-driven research, bridging clinical practice with innovation to improve patient outcomes and global cardiovascular health.

Profiles: Scopus | ORCID | ResearchGate

Featured Publications

  • Yildirim, S. E., Yildirim, T., Kırış, T., & Avci, E. (2025, October). Prognostic value of the NAPLES score and serum uric acid in chronic coronary syndrome: Evidence from time-dependent ROC and time-varying hazard ratio analyses. Journal of Clinical Medicine, 14(20), 7416. https://doi.org/10.3390/jcm14207416

  • Tiryaki, M. M., Yılmaz, C., Ince, H. S., Karaca, B., Kayaalti Esin, F., & Kırış, T. (2025, September). Neutrophil percentage-to-albumin ratio as a predictor of in-hospital mortality in infective endocarditis. Biomarkers in Medicine, 19(17), 1–8. https://doi.org/10.1080/17520363.2025.2562554

  • Akkan, G., Kırış, T., Esin, F., & Karaca, M. (2025, May). Evaluation of mortality and hospitalization due to decompensated heart failure and appropriate shocks in reduced ejection fraction in patients with an implantable cardioverter–defibrillator according to a novel tissue Doppler echocardiographic method. Journal of Clinical Medicine, 14(9), 3226. https://doi.org/10.3390/jcm14093226

  • Esin, F., Bozkurt, H., Palac, B., Akar, B., Kırış, T., Özdemir, E., & Karaca, M. (2025, February). The impact of pleural effusion on long-term mortality in patients undergoing transcatheter aortic valve implantation. Journal of Clinical Medicine, 14(5), 1596. https://doi.org/10.3390/jcm14051596

  • Usta, A., Sancakli Usta, C., Lafci, D., Kırış, T., & Avci, E. (2024, December). Contrast induced nephropathy in women with infertility undergoing hysterosalpingography. Reproductive Biology and Endocrinology, 22(1). https://doi.org/10.1186/s12958-024-01334-3

Oguz Ozcelik | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Prof. Dr. Oguz Ozcelik | Medicine and Health Sciences | Best Researcher Award

Kastamonu University | Turkey

Dr. Oğuz Özçelik (MD, PhD) is a distinguished Professor at Kastamonu University, Turkey, widely recognized for his pioneering work in exercise physiology, metabolism, and oxidative stress. His academic foundation in medicine and physiology has driven decades of impactful research exploring the complex relationships between aerobic fitness, respiratory regulation, and metabolic health. Through rigorous experimental design and translational insights, he has advanced understanding of how exercise modulates physiological and biochemical responses in both healthy and clinical populations. Dr. Oğuz Özçelik’s scientific contributions span more than forty peer-reviewed publications in international journals, reflecting depth, innovation, and clinical relevance. His notable works include studies on the relationship between aerobic fitness levels and isocapnic buffering periods during incremental exercise tests (Cellular and Molecular Biology, 2017, cited by 132), the effects of body mass index on maximal work production and aerobic capacity (Physiological Research, 2004, cited by 84), and the role of nesfatin-1 in glucose tolerance and depressive disorders (Physiological Research, 2016; Psychiatry Investigation, 2018). With an h-index of 13 and more than 474 citations, his scholarly influence demonstrates sustained research excellence. Dr. Oğuz Özçelik’s current investigations focus on the hormonal and metabolic adaptations to exercise and their relevance to neuroendocrine and cardiometabolic health. His leadership, academic rigor, and enduring contributions to human performance and biomedical science exemplify the highest standards of professional achievement and research integrity within the global scientific community.

Profile: Scopus | Google Scholar | ORCID

Featured Publications

  1. Algul, S., Ozcelik, O., & Yilmaz, B. (2017). Evaluation of relationship between aerobic fitness level and range of isocapnic buffering periods during incremental exercise test. Cellular and Molecular Biology, 63(3), 78–82.

  2. Ozcelik, O., Aslan, M., Ayar, A., & Kelestimur, H. (2004). Effects of body mass index on maximal work production capacity and aerobic fitness during incremental exercise. Physiological Research, 53(2), 165–170.

  3. Algul, S., Ozkan, Y., & Ozcelik, O. (2016). Serum nesfatin-1 levels in patients with different glucose tolerance levels. Physiological Research, 65(6), 979–985.

  4. Ozcelik, O., Ward, S. A., & Whipp, B. J. (1999). Effect of altered body CO₂ stores on pulmonary gas exchange dynamics during incremental exercise in humans. Experimental Physiology, 84(5), 999–1011.

  5. Algul, S., & Ozcelik, O. (2018). Evaluating the levels of nesfatin-1 and ghrelin hormones in patients with moderate and severe major depressive disorders. Psychiatry Investigation, 15(2), 214–218.

Andrej Sirek | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Dr. Andrej Sirek | Medicine and Health Sciences | Best Researcher Award

University Hospital Basel | Switzerland

Dr. Andrej Sirek is a dedicated Pathology Resident at the University Hospital Basel, Institute of Medical Genetics and Pathology, where he is actively shaping his career at the intersection of clinical diagnostics and medical research. With his educational foundation built in leading European institutions, Dr. Andrej Sirek has developed a strong grounding in medical genetics, histopathology, and laboratory sciences, which now supports his dual role as both clinician and researcher. His residency provides him with exposure to complex pathology cases while also allowing him to engage in research that seeks to bridge genetic profiling and diagnostic pathology, with the long-term aim of contributing to precision medicine and early disease detection. Currently, he has completed one research project and is progressing with another, both expected to yield indexed publications in the near future. Despite being at an early stage of his academic career, his commitment to innovation in pathology has already been recognized with a nomination for the Best Researcher Award. He maintains active membership in several professional organizations, including SGPATH, ÖGPATH, SGZ, and ESP, which strengthens his global collaborations and engagement with the wider pathology community. While he has yet to publish peer-reviewed articles, his ongoing research demonstrates his potential to make impactful contributions to the field. His academic and professional journey underscores the promise of a new generation of clinician-scientists who integrate advanced diagnostic techniques with research innovation to improve patient care. Dr. Andrej Sirek’s trajectory highlights his dedication, scholarly potential, and commitment to excellence in pathology and medical genetics.

Profile: ORCID

Featured Publications

Dr. Andrej Sirek has contributed to impactful research in pathology, focusing on diagnostic innovations, tumor biology, and clinicopathological correlations. Key recent publications include:

Sirek, A., Hench, I. B., Hench, J., Alborelli, I., Gross, M. W., Jakscha, J., Schaller, P., Nagel, G., Baumhoer, D., & Tzankov, A. (2025). Recurrent clonal radiotherapy-associated fibroepithelial polyp of the pharynx: Do low grade radiogenic stromal tumours exist? Case report.

Sobottka, B., Vetter, V., Banaei-Esfahani, A., Nowak, M., Lorch, A., Sirek, A., Mertz, K. D., Brunelli, M., Berthold, D., de Leval, L., et al. (2024). Immune phenotype-genotype associations in primary clear cell renal cell carcinoma and matched metastatic tissue.

Nicolas Leuenberger | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Published on by Forensic Scientist

Dr. Nicolas Leuenberger | Biochemistry, Genetics and Molecular Biology | Best Researcher Award

Swiss laboratory for Doping Analyses | Switzerland

Dr. Nicolas Leuenberger is a distinguished Privat-docent and Research Manager at the Swiss Laboratory for Doping Analyses, University Hospital of Lausanne. With a proven track record in forensic science and anti-doping research, he has contributed significantly to advancing methodologies for detecting blood doping and other performance-enhancing practices. His leadership in managing research projects, mentoring graduate students, and fostering international collaborations has positioned him as an influential figure in forensic and biomedical sciences.

Professional Profile

Scopus

Education

Dr. Nicolas Leuenberger holds a PhD in Biomedical Sciences and advanced qualifications in forensic and medical sciences, which laid the foundation for his career in anti-doping research. His academic background integrates molecular biology, biochemistry, and forensic medicine, enabling him to explore novel biomarkers of blood manipulation and enhance anti-doping practices worldwide.

Experience

With extensive experience as Research Manager at the Swiss Laboratory for Doping Analyses, Dr. Nicolas Leuenberger oversees both research operations and biological unit management. He directs master’s and PhD projects, guiding students from experimental design to thesis completion. As part of the LAD management team, he coordinates grant applications, establishes ISO-accredited protocols, and supervises multidisciplinary collaborations with hospital units and global anti-doping laboratories. His consultancy roles with Novartis Pharma Schweiz AG, the Research Grants Council of Hong Kong, and the World Anti-Doping Agency further demonstrate his expertise and international recognition.

Research Interests

Dr. Nicolas Leuenberger’s research focuses on the discovery of innovative biomarkers for blood doping, particularly through the fields of ironomics and transcriptomics. His pioneering work on erythroferrone and hepcidin as indicators of blood manipulation has reshaped anti-doping science. Currently, he is advancing mRNA biomarker detection from dried blood spots, enabling more accurate detection of autologous blood transfusions and micro-dose EPO administration. His commitment lies in developing cutting-edge forensic tools that safeguard the integrity of sports and public health.

Awards

Dr. Nicolas Leuenberger has been widely recognized for his contributions to forensic and anti-doping science. His editorial appointment as Associate Editor of Frontiers in Sport and Active Living and his membership in the Swiss Haematology Society underscore his professional standing. He has also been invited as an expert reviewer for the World Anti-Doping Agency and other international bodies, reflecting his global impact on anti-doping policy and scientific innovation.

Publications

Dr. Nicolas Leuenberger has authored over 45 peer-reviewed publications in leading scientific journals, significantly contributing to anti-doping and forensic biomarker research. A selection of his highly cited works includes:

1. Detection of erythropoiesis-stimulating agents in human anti-doping control: Past, present and future
Journal: Drug Testing and Analysis
Published on: July 2012

2. Circulating microRNAs as Biomarkers for Detection of Autologous Blood Transfusion
Journal: PLoS ONE
Published on: June 2013

3. Circulating microRNAs: The Future of Biomarkers in Anti-doping Field
Journal: Drug Testing and Analysis
Published on: December 2015

4. Autologous Blood Transfusion in Sports: Emerging Biomarkers
Journal: Transfusion Medicine Reviews
Published on: May 2016

5. mRNA Biomarkers in Dried Blood Spots May Improve Detection of Autologous Blood Micro-Transfusions Using an Individualized Approach
Journal: Haematologica
Published on: August 2025

6. High Pretransplant Levels of Erythroferrone Are Predictive for 1-Year All-Cause Mortality and Acute Cellular Rejection after Heart Transplantation
Journal: The Journal of Heart and Lung Transplantation
Published on: January 2025

7. New Transcriptomic Biomarkers for Detection of the Recombinant Human Erythropoietin (rHuEPO) MirCERA in Horses
Journal: Frontiers in Veterinary Science
Published on: September 2024

8. Comparison between standard hematological parameters and blood doping biomarkers in dried blood spots within the athlete population of Swiss Sport Integrity
Journal: Haematologica
Published on: September 2024

Conclusion

Dr. Nicolas Leuenberger exemplifies scientific excellence through his pioneering research in anti-doping biomarker discovery, his leadership at the Swiss Laboratory for Doping Analyses, and his dedication to mentoring the next generation of forensic scientists. His contributions have not only advanced the global fight against blood doping but also strengthened the integrity of competitive sports. For these reasons, he is a highly deserving candidate for the Best Researcher Award.

Roya Mirzaei | Molecular Biology | Best Researcher Award

Published on by Forensic Scientist

Dr. Roya Mirzaei | Molecular Biology | Best Researcher Award

Shahid Beheshti University of Medical of sciences | Iran

Dr. Roya Mirzaei is a distinguished Iranian toxicologist and biomedical researcher, currently serving as a Postdoctoral Research Fellow at the Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences (2023–2025). Her academic journey encompasses a Ph.D. in Toxicology (2017–2022) and an MSc in Toxicology (2013–2015) from the Islamic Azad University of Tehran Medical Sciences, following a Bachelor’s degree in Medical Laboratory Sciences from Hamedan University of Medical Sciences (2013). Dr. Mirzaei’s research is deeply rooted in cancer biology, immunotherapy, and molecular toxicology, with a particular focus on the development of recombinant antibodies and the exploration of natural toxins for therapeutic applications. Her prolific contributions to scientific literature and active participation in peer review processes underscore her commitment to advancing medical science.

Professional profile👤

Google Scholar

ORCID

Scopus

Strengths for the Awards✨

Dr. Roya Mirzaei demonstrates exceptional strength in interdisciplinary cancer research, toxicology, and immunopharmacology. With a Ph.D. in Toxicology and ongoing postdoctoral fellowship at the Shahid Beheshti University of Medical Sciences, her research trajectory reflects depth, innovation, and collaboration. Her scientific contributions include 16 peer-reviewed publications, many of which explore novel anti-cancer therapeutics using recombinant antibodies, mitochondrial targeting, and venom-derived compounds. Notably, her publication in high-impact journals like International Immunopharmacology (IF: 5.71) and Environmental Science and Pollution Research (IF: 5.8) marks her as a front-runner in translational research.

🎓 Education

  • Postdoctoral Research Fellow
    Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences (2023–2025)

  • Ph.D. in Toxicology
    Faculty of Pharmacy, Islamic Azad University of Tehran Medical Sciences (2017–2022)

  • MSc in Toxicology
    Faculty of Pharmacy, Islamic Azad University of Tehran Medical Sciences (2013–2015)

  • Bachelor’s Degree in Medical Laboratory Sciences
    Hamedan University of Medical Sciences (2013)

💼 Professional Experience

  • Scientific Researcher
    Recombinant Proteins Department, Motamed Cancer Institute (2021–2023)
    Dr. Mirzaei played a pivotal role in designing and implementing studies, collecting data, and analyzing results, particularly focusing on cancer stem cells and bi-specific antibodies.

  • Research Assistant
    Biotechnology Department, Pasteur Institute of Iran (2014–2018)
    She collaborated with students, provided research guidance, and executed various experimental techniques, contributing to projects involving venom-derived compounds and gene expression studies.

🔬 Research Interests On Molecular Biology

Dr. Mirzaei’s research interests are centered on the cellular and molecular mechanisms involved in cancer and its immunotherapy. She is particularly intrigued by the rapidly evolving fields of tumor immunology and cancer biology, employing both in vitro and in vivo models, as well as bioinformatics tools, to unravel complex biological processes. Her work often intersects with areas such as cellular immunology, cell biology, and the development of novel therapeutic strategies.

🏆 Awards & Honors

  • Top Researcher
    Student Section, Islamic Azad University of Medical Sciences, Tehran-Iran (2018 & 2023)

  • Editorial Board Member
    26th Edition of International Conference on Oncology and Cancer Research, Pencis (2025)

  • Memberships

    • Society of Toxicology (SOT), USA – Postdoctoral Member (2021–Present)

    • Iranian Society of Toxicology (IranTox) (2018–Present)

    • Iranian Society of Physiology and Pharmacology (PHYPHA) (2022–Present)

  • Educational Contributions

    • Co-authored the “IQB: Decennial Iran Question Bank” for Ph.D. Toxicology exams (2018)

    • Translated the latest edition of “Cecil Textbook of Medicine: Cardiovascular Diseases” into Persian (2021)

    • Conducted an online course on Clinical Toxicology via Faradars (2022)

📚 Publications

Dr. Mirzaei has an extensive list of publications in reputable journals. Below are selected works with hyperlinks, publication years, journals, and citation information:

  1. The Recombinant Anti-MET/EpCAM Bispecific Antibody Fragment: A Promising Novel Therapeutic Approach for Breast Cancer Treatment
    Investigational New Drugs, 2025.
    Link
    Cited by: 3 articles

  2. Exploring the Potential of Mitochondria-Targeted Drug Delivery for Enhanced Breast Cancer Therapy
    International Journal of Breast Cancer, 2025.
    Link
    Cited by: 2 articles

  3. Strain-Specific Effects of Probiotics on Depression and Anxiety: A Meta-Analysis
    Gut Pathogens, 2024.
    Link
    Cited by: 5 articles

  4. Production of Novel Recombinant Anti-EpCAM Antibody as Targeted Therapy for Breast Cancer
    International Immunopharmacology, 2023.
    Link
    Cited by: 6 articles

  5. Increased Risk of Primary Ovarian Insufficiency by High-Fructose Diet: A 90-Day Hormonal and Immunohistochemical Study in Wistar Rats
    Environmental Science and Pollution Research, 2022.
    Link
    Cited by: 3 articles

  6. The Role of High-Fructose Diet in Liver Function of Rodent Models: A Systematic Review of Molecular Analysis
    Iranian Biomedical Journal, 2023.
    Link
    Cited by: 2 articles

  7. Repurposing the Drug, Ivermectin, in COVID-19: Toxicological Points of View
    European Journal of Medical Research, 2022.
    Link
    Cited by: 4 articles

  8. Development of a MET-Targeted Single-Chain Antibody Fragment as an Anti-Oncogene Targeted Therapy for Breast Cancer
    Investigational New Drugs, 2023.
    Link
    Cited by: 5 articles

  9. Synthesized Anti-HER2 Trastuzumab-MCC-DM1 Conjugate: An Evaluation of Efficacy and Cytotoxicity
    Iranian Journal of Immunology, 2023.
    Link
    Cited by: 2 articles

  10. Increased Risk of Cerebral Dysfunction by High-Fructose Diet Consumption: A 90-Day Study in Female Rats
    Health Biotechnology and Biopharma, 2023.
    Link
    Cited by: 1 article

🧾 Conclusion

Dr. Roya Mirzaei exemplifies the qualities of a dedicated and innovative researcher in the fields of toxicology and cancer biology. Her extensive academic background, coupled with her hands-on experience in leading research institutions, has led to significant contributions to scientific knowledge, particularly in the development of targeted therapies and the understanding of dietary impacts on health. Her commitment to education, as evidenced by her teaching and translation work, further highlights her dedication to the dissemination of scientific knowledge. Dr. Mirzaei’s achievements make her a deserving candidate for recognition and accolades in her field.

Zhongzhen Su | Medicine | Best Researcher Award

Published on by Forensic Scientist

Dr. Zhongzhen Su | Medicine | Best Researcher Award

The Fifth Affiliated Hospital of Sun Yat-sen University |China

Dr. Zhongzhen Su is a renowned medical professional with over two decades of expertise in abdominal ultrasound diagnosis and liver cancer interventional therapy. Currently serving as the Director of the Ultrasound Medicine Department at the Fifth Affiliated Hospital of Sun Yat-sen University, he has made pivotal contributions in early liver cancer detection and fibrosis assessment. Recognized as a “High-level Talent in Zhuhai” and a “Guangdong Outstanding Young Medical Talent”, Dr. Su has significantly enhanced survival outcomes for cirrhotic patients through innovative imaging techniques.

Professional profile👤

Scopus

Strengths for the Awards✨

  1. Established Academic and Research Record:

    • 48 SCI publications with an H-index of 28 and 1,000+ citations, indicating consistent and influential contributions.

    • Highest publication impact factor of 14.3, demonstrating recognition in high-quality journals.

  2. Innovative Contributions:

    • Two patents (e.g., tumor ultrasound phantom, fibrosis prediction model) and innovative developments in liver cancer diagnostics and ablation.

    • Led 18 completed and 1 ongoing research projects, including National Natural Science Foundation grants.

  3. Clinical and Educational Impact:

    • Pioneered early detection and ultrasound-guided treatment of liver cancer, improving survival rates.

    • Trained over 50 postgraduates, indicating a significant contribution to academic mentorship.

  4. Recognitions and Leadership:

    • Recognized as a “High-level Talent in Zhuhai” and “Guangdong Outstanding Young Medical Talent”.

    • Serves as Director of Ultrasound Medicine and holds leadership roles in national professional associations.

  5. Interdisciplinary and AI Integration:

    • Engaged in AI-based fibrosis assessment and multicenter collaborations, showcasing forward-looking research alignment.

🎓 Education

Dr. Zhongzhen Su earned his Ph.D. in Imaging and Nuclear Medicine from Sun Yat-sen University, one of China’s top medical institutions. His academic foundation combines clinical depth with scientific rigor, forming the bedrock for his ongoing advancements in ultrasound-guided interventions and diagnostic radiology.

👨‍⚕️ Experience

With over 20 years of clinical and academic experience, Dr. Zhongzhen Su has held key roles, including Deputy Dean of the Fifth Affiliated Hospital and now Director of Ultrasound Medicine. His leadership has been instrumental in establishing state-of-the-art interventional ultrasound programs, supervising over 50 postgraduates, and leading multicenter clinical trials focused on liver health.

🔬 Research Interest On Medicine

Dr. Zhongzhen Su primary research interests lie in abdominal ultrasound diagnosis, interventional ultrasound for liver cancer, quantitative assessment of liver fibrosis, and post-ablation evaluation techniques. He is also exploring AI-based models for early-stage fibrosis and cancer detection, which promise transformative impacts in personalized medicine.

🏆 Awards

Dr. Zhongzhen Su is a three-time recipient of the Guangdong Science and Technology Awards 🏅, reflecting his leadership in ultrasound-guided interventional innovation. He has also been honored as a “High-level Talent in Zhuhai” and a “Guangdong Outstanding Young Medical Talent”, distinctions reserved for top-tier professionals in the region’s medical community.

📚 Publications

1. Nomogram Using Bi-modal Imaging for Predicting Low-level HER2 Expression Status in Breast Cancer

  • Authors: Xingyu Liang, Jiamin Chen, Jiawei Tian, Xin Wen

  • Journal: European Journal of Radiology

  • Year: 2025

2. Combination of CT/MRI LI-RADS With Second-Line Contrast-Enhanced Ultrasound Using Sulfur Hexafluoride or Perfluorobutane for Diagnosing Hepatocellular Carcinoma in High-Risk Patients

  • Authors: Yu Li, Sheng Li, Qing Li, Lingling Li, Jianhua Zhou

  • Journal: Korean Journal of Radiology

  • Year: 2025

  • Citations: 0​

3. Doppler Ultrasound Imaging and Shear Wave Elastography for Evaluation of Interstitial Fibrosis/Tubular Atrophy in IgA Nephropathy

  • Authors: Jiaxin Chen, Shuqing Wang, Qunyan Wu, Zhongzhen Su, Yuhong Lin

  • Journal: Abdominal Radiology

  • Year: 2025

4. Tertiary Lymphoid Structure Formation Induced by LIGHT-Engineered and Photosensitive Nanoparticles-Decorated Bacteria Enhances Immune Response Against Colorectal Cancer

  • Authors: Lijun Hu, Li Tan, Shaohui Deng, Honglin Gao, Yujie Jiang, Chen Qiu, Hui Chen, Zecong Xiao, Xintao Shuai, Zhongzhen Su

  • Journal: Biomaterials

  • Year: 2025

  • Citations: 6​

5. Histopathological Diagnosis of Microvascular Invasion in Hepatocellular Carcinoma: Is It Reliable?

  • Authors: Liujun Li, Chaoqun Wu, Feile Ye, Zhou Xuan, Xiaoli Zhang, Jianping Li, Jia Zhou, Zhongzhen Su

  • Journal: World Journal of Gastroenterology

  • Year: 2025

6. Radiomics Diagnosis of Microvascular Invasion in Hepatocellular Carcinoma Using 3D Ultrasound and Whole-Slide Image Fusion

  • Authors: Liujun Li, Shaodong Wang, Jiaxin Chen, Yao Lu, Zhongzhen Su

  • Journal: Small Methods

  • Year: 2025

7. Model Based on Ultrasound and Clinicopathological Characteristics for Early Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

  • Authors: Xin Wen, Jiamin Chen, Jing Zhong, Yuhong Lin, Zhongzhen Su

  • Journal: Quantitative Imaging in Medicine and Surgery

  • Year: 2024

  • Citations: 1​

8. Development and Validation of an Individualized Nomogram for Predicting Patent Foramen Ovale-Associated Stroke: Patent Foramen Ovale Morphology-Based Analysis

  • Authors: Qin Zhang, Mochao Xiao, Wuzhu Lu, Zhongzhen Su, Xiaobo Chen

  • Journal: Echocardiography

  • Year: 2024

🧾 Conclusion

In summary, Dr. Zhongzhen Su stands out as a visionary ultrasound expert and medical educator, having redefined interventional standards in liver cancer therapy and fibrosis evaluation. His trailblazing research, prolific publication record, and dedication to clinical excellence make him an ideal nominee for the Best Researcher Award at the FORENSIC SCIENTIST AWARDS. 🏅🔍